Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts

Journal of Rheumatology

Volumn 42, Issue 3, 2015, Pages 456-463

  Cutolo, Maurizio ^a   Montagna, Paola ^a   Brizzolara, Renata ^a   Smith, Vanessa ^c   Alessandri, Elisa ^a   Villaggio, Barbara ^b   Sulli, Alberto ^a   Tavilla, Pietro Paolo ^b   Pizzorni, Carmen ^a   Soldano, Stefano ^b  

^a Clinical Academic Unit of Rheumatology   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Endothelin 1; Endothelin receptor antagonists; Extracellular matrix; Human skin fibroblasts; Skin fibrosis; Systemic sclerosis

Indexed keywords

ACT 132577; ALPHA SMOOTH MUSCLE ACTIN; BOSENTAN; COLLAGEN TYPE 1; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FIBRONECTIN; MACITENTAN; UNCLASSIFIED DRUG; ACT-132577; ACTIN; ENDOTHELIN A RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; DRUG EFFECTS; FIBROBLAST; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN;

ACTINS; AGED; DOWN-REGULATION; ENDOTHELIN A RECEPTOR ANTAGONISTS; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SKIN; SULFONAMIDES;

EID: 84923864408     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141070     Document Type: Article

References (33)

1. Bhattacharyya S, Wey J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012;8:42-54.
2. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012;180:1340-55.
3. Wynn T, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-40.
4. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010;152:159-66.
5. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
6. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500-3.
7. Leask A. Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis Tissue Repair 2010;3:8.
8. Lagares D, García-Fernández RA, Jiménez CL, Magán-Marchal N, Busnadiego O, Lamas S, et al. Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis. Arthritis Rheum 2010;62:878-89.
9. Shi-wen X, Rodríguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006;26:5518-27.
10. Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology 2010;49:1336-45.
11. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
12. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield B, Treiber A, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45.
13. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011;67:977-84.
14. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
15. Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, et al. Endothelin is a downstream mediator of profibrotic response of transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007;56:4189-94.
16. Soldano S, Montagna P, Brizzolara R, Ferrone C, Parodio A, Sulli A, et al. Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients. Reumatismo 2012;64:326-34.
17. Corallo C, Pecetti G, Iglarz M, Volpi N, Franci D, Montella A, et al. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings. J Biol Regular Homeost Agents 2013;27:455-62.
18. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-12.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001;25:402-8.
20. Weng CM, Yu CC, Kuo ML, Chen BC, Lin CH. Endothelin-1 induces connective tissue growth factor expression in human lung fibroblasts by ETAR-dependent JNK/AP-1 pathway. Biochem Pharmacol 2014;88:402-11.
21. Bruderer S, Marjason J, Sidharta PN, Dingemanse J. Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology 2013;91:331-8.
22. Sidharta PN, van Giersbergen PL, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol 2013;53:1131-8.
23. Leask A. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis. Pharmacol Res 2011;63:502-3.
24. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, Iwasa N, et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010;121:2407-18.
25. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011;179:1074-80.
26. Karasek MA. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease? Med Hypotheses 2007;68:650-5.
27. Manetti M, Guiducci S, Matucci-Cerinic M. The origin of the myofibroblast in fibroproliferative vasculopathy: does the endothelial cell steer the pathophysiology of systemic sclerosis? Arthritis Rheum 2011;63:2164-7.
28. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-61.
29. Mouthon L, Mehrenberger M, Teixeira l, Fakhouri F, Bérezné A, Guillevin L, et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011;42:95-102.
30. Sulli A, Soldano S, Pizzorni C, Montagna P, Secchi ME, Villaggio B, et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009;36:1235-9.
31. Cutolo M. Disease modification in systemic sclerosis. Do integrated approaches offer new challenges? Z Rheumatol 2013;72:326-8.
32. Cutolo M, Zampogna G, Vremis L, Smith V, Pizzorni C, Sulli A. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 2013;40:40-5.
33. Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010;6:578-87.